Loading...

Sawyers Charles

TitleProfessor
InstitutionUniversity of California Los Angeles
DepartmentMedicine
Address11-934 Factor Building
CAMPUS - 167817
Phone(310) 206-5585
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    The MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity Center
    NIH/NCI U54CA224079Sep 30, 2017 - Aug 31, 2019
    Role: Principal Investigator
    Defining the Role of ERG in Modulating the AR Cistrome and Antiandrogen Sensitivity
    NIH/NCI R01CA193837Apr 1, 2015 - Mar 31, 2020
    Role: Principal Investigator
    Understanding Resistance to Next Generation Antiandrogens
    NIH/NCI R01CA155169May 1, 2012 - Dec 31, 2022
    Role: Principal Investigator
    Translational Research in Oncology Training Program
    NIH/NCI T32CA160001Jul 11, 2011 - Jul 31, 2021
    Role: Principal Investigator
    REGULATION OF THE PTEN GENE IN PROSTATE CANCER
    NIH/NCI R01CA087079Jul 17, 2000 - Jun 30, 2005
    Role: Principal Investigator
    Mouse Models for Human Prostate Cancer
    NIH/NCI U01CA084128Sep 30, 1999 - Mar 31, 2010
    Role: Principal Investigator
    STEM CELL GENES IN PROSTATE GROWTH AND DIFFERENTIATION
    NIH/NIDDK R01DK052673Mar 27, 1998 - Feb 28, 2003
    Role: Principal Investigator
    Molecular Biology in Clinical Oncology Workshop
    NIH/NCI R25CA057732Sep 30, 1992 - May 31, 2021
    Role: Principal Investigator
    P53 IN CHRONIC MYELOGENOUS LEUKEMIA
    NIH/NCI K11CA001551Jul 16, 1990 - Jun 30, 1995
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, Sboner A, Zafeiriou Z, Miranda S, Bielski CM, Penson AV, Tolonen C, Huang FW, Robinson D, Wu YM, Lonigro R, Garraway LA, Demichelis F, Kantoff PW, Taplin ME, Abida W, Taylor BS, Scher HI, Nelson PS, de Bono JS, Rubin MA, Sawyers C, Chinnaiyan AM. The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018 Apr 02. PMID: 29610475.
      View in: PubMed
    2. Settleman J, Sawyers C, Hunter T. Challenges in validating candidate therapeutic targets in cancer. Elife. 2018 Feb 08; 7. PMID: 29417929.
      View in: PubMed
    3. Fox JJ, Gavane SC, Blanc-Autran E, Nehmeh S, Gönen M, Beattie B, Vargas HA, Schöder H, Humm JL, Fine SW, Lewis JS, Solomon SB, Osborne JR, Veach D, Sawyers C, Weber WA, Scher HI, Morris MJ, Larson SM. Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol. 2018 Feb 01; 4(2):217-224. PMID: 29121144.
      View in: PubMed
    4. Abida W, Sawyers C. Targeting DNA Repair in Prostate Cancer. J Clin Oncol. 2018 Apr 01; 36(10):1017-1019. PMID: 29369701.
      View in: PubMed
    5. Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers C, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. Eur Urol. 2018 May; 73(5):715-723. PMID: 29258679.
      View in: PubMed
    6. Hieronymus H, Iaquinta PJ, Wongvipat J, Gopalan A, Murali R, Mao N, Carver BS, Sawyers C. Deletion of 3p13-14 locus spanning FOXP1 to SHQ1 cooperates with PTEN loss in prostate oncogenesis. Nat Commun. 2017 10 20; 8(1):1081. PMID: 29057879.
      View in: PubMed
    7. Shah N, Wang P, Wongvipat J, Karthaus WR, Abida W, Armenia J, Rockowitz S, Drier Y, Bernstein BE, Long HW, Freedman ML, Arora VK, Zheng D, Sawyers C. Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. Elife. 2017 09 11; 6. PMID: 28891793.
      View in: PubMed
    8. Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, Pradhan N, Arnold A, Walsh MF, Li Y, Balakrishnan AR, Syed A, Prasad M, Nafa K, Carlo MI, Cadoo KA, Sheehan M, Fleischut MH, Salo-Mullen E, Trottier M, Lipkin SM, Lincoln A, Mukherjee S, Ravichandran V, Cambria R, Galle J, Abida W, Arcila ME, Benayed R, Shah R, Yu K, Bajorin DF, Coleman JA, Leach SD, Lowery MA, Garcia-Aguilar J, Kantoff PW, Sawyers C, Dickler MN, Saltz L, Motzer RJ, O'Reilly EM, Scher HI, Baselga J, Klimstra DS, Solit DB, Hyman DM, Berger MF, Ladanyi M, Robson ME, Offit K. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA. 2017 09 05; 318(9):825-835. PMID: 28873162.
      View in: PubMed
    9. Bose R, Karthaus WR, Armenia J, Abida W, Iaquinta PJ, Zhang Z, Wongvipat J, Wasmuth EV, Shah N, Sullivan PS, Doran MG, Wang P, Patruno A, Zhao Y, Zheng D, Schultz N, Sawyers C. ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis. Nature. 2017 06 29; 546(7660):671-675. PMID: 28614298.
      View in: PubMed
    10. Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, Danila D, Rathkopf D, Morris M, Slovin S, McLaughlin B, Curtis K, Hyman DM, Durack JC, Solomon SB, Arcila ME, Zehir A, Syed A, Gao J, Chakravarty D, Vargas HA, Robson ME, Joseph V, Offit K, Donoghue MTA, Abeshouse AA, Kundra R, Heins ZJ, Penson AV, Harris C, Taylor BS, Ladanyi M, Mandelker D, Zhang L, Reuter VE, Kantoff PW, Solit DB, Berger MF, Sawyers C, Schultz N, Scher HI. Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO Precis Oncol. 2017 Jul; 2017. PMID: 28825054.
      View in: PubMed
    11. Lawler M, Haussler D, Siu LL, Haendel MA, McMurry JA, Knoppers BM, Chanock SJ, Calvo F, The BT, Walia G, Banks I, Yu PP, Staudt LM, Sawyers C. Sharing Clinical and Genomic Data on Cancer - The Need for Global Solutions. N Engl J Med. 2017 05 25; 376(21):2006-2009. PMID: 28538124.
      View in: PubMed
    12. Sawyers C. Dorcas Cummings Lecture. Cold Spring Harb Symp Quant Biol. 2016; 81:291-295. PMID: 28280229.
      View in: PubMed
    13. Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, Wongvipat J, Ku SY, Gao D, Cao Z, Shah N, Adams EJ, Abida W, Watson PA, Prandi D, Huang CH, de Stanchina E, Lowe SW, Ellis L, Beltran H, Rubin MA, Goodrich DW, Demichelis F, Sawyers C. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science. 2017 01 06; 355(6320):84-88. PMID: 28059768.
      View in: PubMed
    14. Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, Goodrich MM, Labbé DP, Gomez EC, Wang J, Long HW, Xu B, Brown M, Loda M, Sawyers C, Ellis L, Goodrich DW. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017 01 06; 355(6320):78-83. PMID: 28059767.
      View in: PubMed
    15. Liu X, Grogan TR, Hieronymus H, Hashimoto T, Mottahedeh J, Cheng D, Zhang L, Huang K, Stoyanova T, Park JW, Shkhyan RO, Nowroozizadeh B, Rettig MB, Sawyers C, Elashoff D, Horvath S, Huang J, Witte ON, Goldstein AS. Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome. Cell Rep. 2016 12 06; 17(10):2596-2606. PMID: 27926864.
      View in: PubMed
    16. Gao D, Zhan Y, Di W, Moore AR, Sher JJ, Guan Y, Wang S, Zhang Z, Murphy DA, Sawyers C, Chi P, Chen Y. A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and Colon. PLoS One. 2016; 11(8):e0161084. PMID: 27536883; PMCID: PMC4990297.
    17. Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 2016 Aug 04; 375(5):443-53. PMID: 27433846.
      View in: PubMed
    18. Siu LL, Lawler M, Haussler D, Knoppers BM, Lewin J, Vis DJ, Liao RG, Andre F, Banks I, Barrett JC, Caldas C, Camargo AA, Fitzgerald RC, Mao M, Mattison JE, Pao W, Sellers WR, Sullivan P, Teh BT, Ward RL, ZenKlusen JC, Sawyers C, Voest EE. Facilitating a culture of responsible and effective sharing of cancer genome data. Nat Med. 2016 05 05; 22(5):464-71. PMID: 27149219; PMCID: PMC4995884.
    19. Drost J, Karthaus WR, Gao D, Driehuis E, Sawyers C, Chen Y, Clevers H. Organoid culture systems for prostate epithelial and cancer tissue. Nat Protoc. 2016 Feb; 11(2):347-58. PMID: 26797458; PMCID: PMC4793718.
    20. Doran MG, Carnazza KE, Steckler JM, Spratt DE, Truillet C, Wongvipat J, Sawyers C, Lewis JS, Evans MJ. Applying 8?Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins. Mol Pharm. 2016 Feb 01; 13(2):683-8. PMID: 26725682; PMCID: PMC4738321.
    21. Agarwal S, Hynes PG, Tillman HS, Lake R, Abou-Kheir WG, Fang L, Casey OM, Ameri AH, Martin PL, Yin JJ, Iaquinta PJ, Karthaus WR, Clevers HC, Sawyers C, Kelly K. Identification of Different Classes of Luminal Progenitor Cells within Prostate Tumors. Cell Rep. 2015 Dec 15; 13(10):2147-58. PMID: 26628377.
      View in: PubMed
    22. Watson PA, Arora VK, Sawyers C. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015 Dec; 15(12):701-11. PMID: 26563462; PMCID: PMC4771416.
    23. Lawler M, Siu LL, Rehm HL, Chanock SJ, Alterovitz G, Burn J, Calvo F, Lacombe D, Teh BT, North KN, Sawyers C. All the World's a Stage: Facilitating Discovery Science and Improved Cancer Care through the Global Alliance for Genomics and Health. Cancer Discov. 2015 Nov; 5(11):1133-6. PMID: 26526696.
      View in: PubMed
    24. Spratt DE, Evans MJ, Davis BJ, Doran MG, Lee MX, Shah N, Wongvipat J, Carnazza KE, Klee GG, Polkinghorn W, Tindall DJ, Lewis JS, Sawyers C. Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. Cancer Res. 2015 Nov 15; 75(22):4688-96. PMID: 26432404; PMCID: PMC4651750 [Available on 11/15/16].
    25. Wheeler DB, Zoncu R, Root DE, Sabatini DM, Sawyers C. Identification of an oncogenic RAB protein. Science. 2015 Oct 09; 350(6257):211-7. PMID: 26338797; PMCID: PMC4600465.
    26. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Sboner A, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers C, Chinnaiyan AM. Integrative Clinical Genomics of Advanced Prostate Cancer. Cell. 2015 Jul 16; 162(2):454. PMID: 28843286.
      View in: PubMed
    27. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers C, Chinnaiyan AM. Integrative clinical genomics of advanced prostate cancer. Cell. 2015 May 21; 161(5):1215-1228. PMID: 26000489; PMCID: PMC4484602.
    28. Schwartz S, Wongvipat J, Trigwell CB, Hancox U, Carver BS, Rodrik-Outmezguine V, Will M, Yellen P, de Stanchina E, Baselga J, Scher HI, Barry ST, Sawyers C, Chandarlapaty S, Rosen N. Feedback suppression of PI3Ka signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kß. Cancer Cell. 2015 Jan 12; 27(1):109-22. PMID: 25544636; PMCID: PMC4293347.
    29. Wanjala J, Taylor BS, Chapinski C, Hieronymus H, Wongvipat J, Chen Y, Nanjangud GJ, Schultz N, Xie Y, Liu S, Lu W, Yang Q, Sander C, Chen Z, Sawyers C, Carver BS. Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling. Mol Cancer Ther. 2015 Jan; 14(1):278-88. PMID: 25381262; PMCID: PMC4297258.
    30. Balbas MD, Burgess MR, Murali R, Wongvipat J, Skaggs BJ, Mundel P, Weins A, Sawyers C. MAGI-2 scaffold protein is critical for kidney barrier function. Proc Natl Acad Sci U S A. 2014 Oct 14; 111(41):14876-81. PMID: 25271328; PMCID: PMC4205655.
    31. Sawyers C, van 't Veer LJ. Reliable and effective diagnostics are keys to accelerating personalized cancer medicine and transforming cancer care: a policy statement from the american association for cancer research. Clin Cancer Res. 2014 Oct 01; 20(19):4978-81. PMID: 25204554.
      View in: PubMed
    32. Karthaus WR, Iaquinta PJ, Drost J, Gracanin A, van Boxtel R, Wongvipat J, Dowling CM, Gao D, Begthel H, Sachs N, Vries RGJ, Cuppen E, Chen Y, Sawyers C, Clevers HC. Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell. 2014 Sep 25; 159(1):163-175. PMID: 25201529; PMCID: PMC4772677.
    33. Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK, Wongvipat J, Kossai M, Ramazanoglu S, Barboza LP, Di W, Cao Z, Zhang QF, Sirota I, Ran L, MacDonald TY, Beltran H, Mosquera JM, Touijer KA, Scardino PT, Laudone VP, Curtis KR, Rathkopf DE, Morris MJ, Danila DC, Slovin SF, Solomon SB, Eastham JA, Chi P, Carver B, Rubin MA, Scher HI, Clevers H, Sawyers C, Chen Y. Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014 Sep 25; 159(1):176-187. PMID: 25201530; PMCID: PMC4237931.
    34. Carethers JM, Coughlin S, Diamond B, Erzurum S, Fried LP, Jameson JL, Kaushansky K, Klotman ME, Lemon S, Mitchell B, Rothman P, Sawyers C, Seidman C, Somlo S. The imperative to invest in science has never been greater. J Clin Invest. 2014 Sep; 124(9):3680-1. PMID: 25180532; PMCID: PMC4151225.
    35. Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, Kitzing T, Zhu N, de Stanchina E, Sawyers C, Armstrong SA, Lewis JS, Sherr CJ, Lowe SW. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev. 2014 Aug 15; 28(16):1800-14. PMID: 25128497; PMCID: PMC4197965.
    36. Hieronymus H, Schultz N, Gopalan A, Carver BS, Chang MT, Xiao Y, Heguy A, Huberman K, Bernstein M, Assel M, Murali R, Vickers A, Scardino PT, Sander C, Reuter V, Taylor BS, Sawyers C. Copy number alteration burden predicts prostate cancer relapse. Proc Natl Acad Sci U S A. 2014 Jul 29; 111(30):11139-44. PMID: 25024180; PMCID: PMC4121784.
    37. Doran MG, Spratt DE, Wongvipat J, Ulmert D, Carver BS, Sawyers C, Evans MJ. Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries. Mol Imaging. 2014; 13. PMID: 25248353; PMCID: PMC4545649.
    38. Blattner M, Lee DJ, O'Reilly C, Park K, MacDonald TY, Khani F, Turner KR, Chiu YL, Wild PJ, Dolgalev I, Heguy A, Sboner A, Ramazangolu S, Hieronymus H, Sawyers C, Tewari AK, Moch H, Yoon GS, Known YC, Andrén O, Fall K, Demichelis F, Mosquera JM, Robinson BD, Barbieri CE, Rubin MA. SPOP mutations in prostate cancer across demographically diverse patient cohorts. Neoplasia. 2014 Jan; 16(1):14-20. PMID: 24563616; PMCID: PMC3924544.
    39. Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers C. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013 Dec 05; 155(6):1309-22. PMID: 24315100; PMCID: PMC3932525.
    40. Brannon AR, Sawyers C. "N of 1" case reports in the era of whole-genome sequencing. J Clin Invest. 2013 Nov; 123(11):4568-70. PMID: 24135144; PMCID: PMC3809802.
    41. Sawyers C, Abate-Shen C, Anderson KC, Barker A, Baselga J, Berger NA, Foti M, Jemal A, Lawrence TS, Li CI, Mardis ER, Neumann PJ, Pardoll DM, Prendergast GC, Reed JC, Weiner GJ. AACR Cancer Progress Report 2013. Clin Cancer Res. 2013 Oct 15; 19(20 Suppl):S4-98. PMID: 24045178.
      View in: PubMed
    42. Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, Arora VK, Yen WF, Cai L, Zheng D, Carver BS, Chen Y, Watson PA, Shah NP, Fujisawa S, Goglia AG, Gopalan A, Hieronymus H, Wongvipat J, Scardino PT, Zelefsky MJ, Jasin M, Chaudhuri J, Powell SN, Sawyers C. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov. 2013 Nov; 3(11):1245-53. PMID: 24027196; PMCID: PMC3888815.
    43. Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager JH, Rix PJ, Chow Maneval E, Chen I, Gönen M, Fleisher M, Larson SM, Sawyers C, Scher HI. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2013 Oct 01; 31(28):3525-30. PMID: 24002508; PMCID: PMC3782148.
    44. Chen Y, Chi P, Rockowitz S, Iaquinta PJ, Shamu T, Shukla S, Gao D, Sirota I, Carver BS, Wongvipat J, Scher HI, Zheng D, Sawyers C. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med. 2013 Aug; 19(8):1023-9. PMID: 23817021; PMCID: PMC3737318.
    45. Sawyers C. Perspective: combined forces. Nature. 2013 Jun 27; 498(7455):S7. PMID: 23803949.
      View in: PubMed
    46. Horning SJ, Haber DA, Selig WK, Ivy SP, Roberts SA, Allen JD, Sigal EV, Sawyers C. Developing standards for breakthrough therapy designation in oncology. Clin Cancer Res. 2013 Aug 15; 19(16):4297-304. PMID: 23719260.
      View in: PubMed
    47. Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y, Sawyers C. Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife. 2013 Apr 09; 2:e00499. PMID: 23580326; PMCID: PMC3622181.
    48. Yoshioka T, Otero J, Chen Y, Kim YM, Koutcher JA, Satagopan J, Reuter V, Carver B, de Stanchina E, Enomoto K, Greenberg NM, Scardino PT, Scher HI, Sawyers C, Giancotti FG. ß4 Integrin signaling induces expansion of prostate tumor progenitors. J Clin Invest. 2013 Feb; 123(2):682-99. PMID: 23348745; PMCID: PMC3561800.
    49. Evans MJ, Holland JP, Rice SL, Doran MG, Cheal SM, Campos C, Carlin SD, Mellinghoff IK, Sawyers C, Lewis JS. Imaging tumor burden in the brain with 89Zr-transferrin. J Nucl Med. 2013 Jan; 54(1):90-5. PMID: 23236019; PMCID: PMC3747823.
    50. Holland JP, Evans MJ, Rice SL, Wongvipat J, Sawyers C, Lewis JS. Annotating MYC status with 89Zr-transferrin imaging. Nat Med. 2012 Oct; 18(10):1586-91. PMID: 23001181; PMCID: PMC3521603.
    51. Mitsiades N, Sung CC, Schultz N, Danila DC, He B, Eedunuri VK, Fleisher M, Sander C, Sawyers C, Scher HI. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res. 2012 Dec 01; 72(23):6142-52. PMID: 22971343; PMCID: PMC3685485.
    52. Cantley LC, Dalton WS, DuBois RN, Finn OJ, Futreal PA, Golub TR, Hait WN, Lozano G, Maris JM, Nelson WG, Sawyers C, Schreiber SL, Spitz MR, Steeg PS. AACR Cancer Progress Report 2012. Clin Cancer Res. 2012 Nov 01; 18(21 Suppl):S1-100. PMID: 22977188.
      View in: PubMed
    53. Hübner A, Mulholland DJ, Standen CL, Karasarides M, Cavanagh-Kyros J, Barrett T, Chi H, Greiner DL, Tournier C, Sawyers C, Flavell RA, Wu H, Davis RJ. JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proc Natl Acad Sci U S A. 2012 Jul 24; 109(30):12046-51. PMID: 22753496; PMCID: PMC3409732.
    54. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 2012 Jul 01; 44(8):852-60. PMID: 22751098; PMCID: PMC3408577.
    55. Hieronymus H, Sawyers C. Traversing the genomic landscape of prostate cancer from diagnosis to death. Nat Genet. 2012 May 29; 44(6):613-4. PMID: 22641202.
      View in: PubMed
    56. Dahlman KB, Parker JS, Shamu T, Hieronymus H, Chapinski C, Carver B, Chang K, Hannon GJ, Sawyers C. Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening. PLoS One. 2012; 7(4):e34414. PMID: 22509301; PMCID: PMC3324507.
    57. Cheng EH, Sawyers C. In cancer drug resistance, germline matters too. Nat Med. 2012 Apr 05; 18(4):494-6. PMID: 22481406.
      View in: PubMed
    58. Ulmert D, Evans MJ, Holland JP, Rice SL, Wongvipat J, Pettersson K, Abrahamsson PA, Scardino PT, Larson SM, Lilja H, Lewis JS, Sawyers C. Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discov. 2012 Apr; 2(4):320-7. PMID: 22576209; PMCID: PMC3351274.
    59. Glickman MS, Sawyers C. Converting cancer therapies into cures: lessons from infectious diseases. Cell. 2012 Mar 16; 148(6):1089-98. PMID: 22424221; PMCID: PMC3465702.
    60. Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers C, Hager JH. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012 Mar 15; 72(6):1494-503. PMID: 22266222; PMCID: PMC3306502.
    61. Sawyers C, Mellinghoff IK. Cancer drug development. Preface. Curr Top Microbiol Immunol. 2012; 355:v-vi. PMID: 23227490.
      View in: PubMed
    62. Sawyers C. The 2011 Gordon Wilson Lecture: overcoming resistance to targeted cancer drugs. Trans Am Clin Climatol Assoc. 2012; 123:114-23; discussion 123-5. PMID: 23303979; PMCID: PMC3540597.
    63. Leder K, Foo J, Skaggs B, Gorre M, Sawyers C, Michor F. Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia. PLoS One. 2011; 6(11):e27682. PMID: 22140458; PMCID: PMC3225363.
    64. Chen Y, Shamu T, Chen H, Besmer P, Sawyers C, Chi P. Visualization of the interstitial cells of cajal (ICC) network in mice. J Vis Exp. 2011 Jul 27; (53). PMID: 21841758; PMCID: PMC3197437.
    65. Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, Lilja H, Molina A, Sawyers C, Fleisher M, Scher HI. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol. 2011 Nov; 60(5):897-904. PMID: 21802835; PMCID: PMC3185163.
    66. Paquette RL, Nicoll J, Chalukya M, Elashoff D, Shah NP, Sawyers C, Spiteri E, Nanjangud G, Rao PN. Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors. Cancer Genet. 2011 Jul; 204(7):392-7. PMID: 21872826.
      View in: PubMed
    67. Suwaki N, Vanhecke E, Atkins KM, Graf M, Swabey K, Huang P, Schraml P, Moch H, Cassidy AM, Brewer D, Al-Lazikani B, Workman P, De-Bono J, Kaye SB, Larkin J, Gore ME, Sawyers C, Nelson P, Beer TM, Geng H, Gao L, Qian DZ, Alumkal JJ, Thomas G, Thomas GV. A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Sci Transl Med. 2011 Jun 01; 3(85):85ra47. PMID: 21632985; PMCID: PMC3303496.
    68. Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, Larson SM, Sawyers C. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A. 2011 Jun 07; 108(23):9578-82. PMID: 21606347; PMCID: PMC3111331.
    69. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers C. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011 May 17; 19(5):575-86. PMID: 21575859; PMCID: PMC3142785.
    70. Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, Moonsamy P, Dahlman K, Miller VA, Costa C, Hannon G, Sawyers C. FAS and NF-?B signalling modulate dependence of lung cancers on mutant EGFR. Nature. 2011 Mar 24; 471(7339):523-6. PMID: 21430781; PMCID: PMC3541675.
    71. Clegg NJ, Couto SS, Wongvipat J, Hieronymus H, Carver BS, Taylor BS, Ellwood-Yen K, Gerald WL, Sander C, Sawyers C. MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors. PLoS One. 2011 Mar 04; 6(3):e17449. PMID: 21394210; PMCID: PMC3048873.
    72. Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P, Cardenal F, Isla D, Provencio M, Cobo M, Insa A, Garcia-Campelo R, Reguart N, Majem M, Viteri S, Carcereny E, Porta R, Massuti B, Queralt C, de Aguirre I, Sanchez JM, Sanchez-Ronco M, Mate JL, Ariza A, Benlloch S, Sanchez JJ, Bivona TG, Sawyers C, Taron M. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res. 2011 Mar 01; 17(5):1160-8. PMID: 21233402.
      View in: PubMed
    73. Solit D, Sawyers C. Drug discovery: How melanomas bypass new therapy. Nature. 2010 Dec 16; 468(7326):902-3. PMID: 21164474.
      View in: PubMed
    74. Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, Fletcher JA, Dewell S, Maki RG, Zheng D, Antonescu CR, Allis CD, Sawyers C. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature. 2010 Oct 14; 467(7317):849-53. PMID: 20927104.
      View in: PubMed
    75. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers C. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A. 2010 Sep 28; 107(39):16759-65. PMID: 20823238; PMCID: PMC2947883.
    76. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers C, Gerald WL. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010 Jul 13; 18(1):11-22. PMID: 20579941; PMCID: PMC3198787.
    77. Sawyers C. Even better kinase inhibitors for chronic myeloid leukemia. N Engl J Med. 2010 Jun 17; 362(24):2314-5. PMID: 20525994.
      View in: PubMed
    78. Chen Y, Sawyers C. Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers. Cancer Cell. 2010 May 18; 17(5):415-6. PMID: 20478521; PMCID: PMC2931314.
    79. Nandana S, Ellwood-Yen K, Sawyers C, Wills M, Weidow B, Case T, Vasioukhin V, Matusik R. Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model. Prostate. 2010 May 01; 70(6):591-600. PMID: 19938013; PMCID: PMC2925264.
    80. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers C. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010 Apr 24; 375(9724):1437-46. PMID: 20398925; PMCID: PMC2948179.
    81. Jung ME, Ouk S, Yoo D, Sawyers C, Chen C, Tran C, Wongvipat J. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J Med Chem. 2010 Apr 08; 53(7):2779-96. PMID: 20218717; PMCID: PMC3180999.
    82. Paquette RL, Nicoll J, Chalukya M, Gondek L, Jasek M, Sawyers C, Shah NP, Maciejewski J. Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib. Leuk Res. 2010 Jun; 34(6):708-13. PMID: 19804904.
      View in: PubMed
    83. Sawyers C. Shifting paradigms: the seeds of oncogene addiction. Nat Med. 2009 Oct; 15(10):1158-61. PMID: 19812578.
      View in: PubMed
    84. Sawyers C. Lessons learned from the development of kinase inhibitors. Clin Adv Hematol Oncol. 2009 Sep; 7(9):588-9. PMID: 20020670.
      View in: PubMed
    85. McGillicuddy LT, Fromm JA, Hollstein PE, Kubek S, Beroukhim R, De Raedt T, Johnson BW, Williams SM, Nghiemphu P, Liau LM, Cloughesy TF, Mischel PS, Parret A, Seiler J, Moldenhauer G, Scheffzek K, Stemmer-Rachamimov AO, Sawyers C, Brennan C, Messiaen L, Mellinghoff IK, Cichowski K. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell. 2009 Jul 07; 16(1):44-54. PMID: 19573811; PMCID: PMC2897249.
    86. Sawyers C. Finding and drugging the vulnerabilities of RAS-dependent cancers. Cell. 2009 May 29; 137(5):796-8. PMID: 19490885.
      View in: PubMed
    87. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, Gerald WL, Sawyers C. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet. 2009 May; 41(5):524-6. PMID: 19396167; PMCID: PMC2898503.
    88. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers C. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009 May 08; 324(5928):787-90. PMID: 19359544; PMCID: PMC2981508.
    89. Parsons JK, Saria EA, Nakayama M, Vessella RL, Sawyers C, Isaacs WB, Faith DA, Bova GS, Samathanam CA, Mitchell R, De Marzo AM. Comprehensive mutational analysis and mRNA isoform quantification of TP63 in normal and neoplastic human prostate cells. Prostate. 2009 Apr 01; 69(5):559-69. PMID: 19142959; PMCID: PMC2875878.
    90. Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, Rosen N, Sawyers C. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res. 2009 Feb 01; 69(3):958-66. PMID: 19176386; PMCID: PMC3219545.
    91. Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E, Nicaise C, Sawyers C. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell. 2008 Dec 09; 14(6):485-93. PMID: 19061839.
      View in: PubMed
    92. Sawyers C. Translational research: are we on the right track? 2008 American Society for Clinical Investigation Presidential Address. J Clin Invest. 2008 Nov; 118(11):3798-801. PMID: 18982165; PMCID: PMC2575723.
    93. Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, Case TC, Ellwood-Yen K, Sawyers C, Bhowmick NA, Blackwell TS, Yull FE, Matusik RJ. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res. 2008 Aug 15; 68(16):6762-9. PMID: 18701501; PMCID: PMC2840631.
    94. Chen Y, Sawyers C, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol. 2008 Aug; 8(4):440-8. PMID: 18674639; PMCID: PMC2574839.
    95. Majumder PK, Grisanzio C, O'Connell F, Barry M, Brito JM, Xu Q, Guney I, Berger R, Herman P, Bikoff R, Fedele G, Baek WK, Wang S, Ellwood-Yen K, Wu H, Sawyers C, Signoretti S, Hahn WC, Loda M, Sellers WR. A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell. 2008 Aug 12; 14(2):146-55. PMID: 18691549; PMCID: PMC2583442.
    96. Sawyers C. The cancer biomarker problem. Nature. 2008 Apr 03; 452(7187):548-52. PMID: 18385728.
      View in: PubMed
    97. Sawyers C. Something lost--something gained: the ASCI begins its second century. J Clin Invest. 2008 Apr; 118(4):1213-4. PMID: 18382722; PMCID: PMC2276814.
    98. Duncan EA, Goetz CA, Stein SJ, Mayo KJ, Skaggs BJ, Ziegelbauer K, Sawyers C, Baldwin AS. IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells. Mol Cancer Ther. 2008 Feb; 7(2):391-7. PMID: 18245668.
      View in: PubMed
    99. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers C. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008 Jan 22; 5(1):e8. PMID: 18215105; PMCID: PMC2211560.
    100. Kaelin WG, Sawyers C, Mihich E. Nineteenth Annual Pezcoller Symposium: hypothesis-driven clinical investigation in cancer. Cancer Res. 2007 Dec 01; 67(23):11102-5. PMID: 18045966.
      View in: PubMed
    101. Sawyers C. Cancer: mixing cocktails. Nature. 2007 Oct 25; 449(7165):993-6. PMID: 17960228.
      View in: PubMed
    102. Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Gambacorti C, Stone RM, Goldman J, Fischer T, O'Brien SG, Reiffers JJ, Mone M, Krahnke T, Talpaz M, Kantarjian HM. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood. 2008 Feb 01; 111(3):1039-43. PMID: 17932248.
      View in: PubMed
    103. Sawyers C. Where lies the blame for resistance--tumor or host? Nat Med. 2007 Oct; 13(10):1144-5. PMID: 17917659.
      View in: PubMed
    104. Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers C. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest. 2007 Sep; 117(9):2562-9. PMID: 17710227; PMCID: PMC1940237.
    105. Jiao J, Wang S, Qiao R, Vivanco I, Watson PA, Sawyers C, Wu H. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res. 2007 Jul 01; 67(13):6083-91. PMID: 17616663.
      View in: PubMed
    106. Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, Golub T, Mellinghoff IK, Davis RJ, Wu H, Sawyers C. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell. 2007 Jun; 11(6):555-69. PMID: 17560336.
      View in: PubMed
    107. Skaggs BJ, Gorre ME, Ryvkin A, Burgess MR, Xie Y, Han Y, Komisopoulou E, Brown LM, Loo JA, Landaw EM, Sawyers C, Graeber TG. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci U S A. 2006 Dec 19; 103(51):19466-71. PMID: 17164333; PMCID: PMC1698443.
    108. Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, Linhart DJ, Glatt KA, Getz G, Onofrio R, Ziaugra L, Levine RL, Gabriel S, Kawaguchi T, O'Neill K, Khan H, Liau LM, Nelson SF, Rao PN, Mischel P, Pieper RO, Cloughesy T, Leahy DJ, Sellers WR, Sawyers C, Meyerson M, Mellinghoff IK. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006 Dec; 3(12):e485. PMID: 17177598; PMCID: PMC1702556.
    109. Ellwood-Yen K, Wongvipat J, Sawyers C. Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens. Cancer Res. 2006 Nov 01; 66(21):10513-6. PMID: 17079473.
      View in: PubMed
    110. Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers C, Mischel PS. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res. 2006 Aug 15; 66(16):7864-9. PMID: 16912159.
      View in: PubMed
    111. Burgess MR, Sawyers C. Treating imatinib-resistant leukemia: the next generation targeted therapies. ScientificWorldJournal. 2006 Aug 11; 6:918-30. PMID: 16906325.
      View in: PubMed
    112. Sawyers C. Will kinase inhibitors have a dark side? N Engl J Med. 2006 Jul 20; 355(3):313-5. PMID: 16855275.
      View in: PubMed
    113. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers C. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006 Jun 15; 354(24):2531-41. PMID: 16775234.
      View in: PubMed
    114. Baek SH, Ohgi KA, Nelson CA, Welsbie D, Chen C, Sawyers C, Rose DW, Rosenfeld MG. Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells. Proc Natl Acad Sci U S A. 2006 Feb 28; 103(9):3100-5. PMID: 16492776; PMCID: PMC1413901.
    115. Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, Sawyers C, Shah N, Stock W, Willman CL, Friend S, Linsley PS. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006 Feb 21; 103(8):2794-9. PMID: 16477019; PMCID: PMC1413797.
    116. Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH, Treiber DK, Patel HK, Zarrinkar PP, Lockhart DJ, Sawyers C, Kuriyan J. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res. 2006 Jan 15; 66(2):1007-14. PMID: 16424036.
      View in: PubMed
    117. Watson PA, Ellwood-Yen K, King JC, Wongvipat J, Lebeau MM, Sawyers C. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res. 2005 Dec 15; 65(24):11565-71. PMID: 16357166.
      View in: PubMed
    118. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J, Sawyers C. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006 Jan; 12(1):122-7. PMID: 16341243.
      View in: PubMed
    119. Koochekpour S, Zhuang YJ, Beroukhim R, Hsieh CL, Hofer MD, Zhau HE, Hiraiwa M, Pattan DY, Ware JL, Luftig RB, Sandhoff K, Sawyers C, Pienta KJ, Rubin MA, Vessella RL, Sellers WR, Sartor O. Amplification and overexpression of prosaposin in prostate cancer. Genes Chromosomes Cancer. 2005 Dec; 44(4):351-64. PMID: 16080200.
      View in: PubMed
    120. Chandra J, Tracy J, Loegering D, Flatten K, Verstovsek S, Beran M, Gorre M, Estrov Z, Donato N, Talpaz M, Sawyers C, Bhalla K, Karp J, Sausville E, Kaufmann SH. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood. 2006 Mar 15; 107(6):2501-6. PMID: 16291594; PMCID: PMC1895739.
    121. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers C, Mischel PS. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005 Nov 10; 353(19):2012-24. PMID: 16282176.
      View in: PubMed
    122. Scher HI, Sawyers C. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005 Nov 10; 23(32):8253-61. PMID: 16278481.
      View in: PubMed
    123. Sawyers C. Update on the use of imatinib mesylate. Clin Adv Hematol Oncol. 2005 Oct; 3(10):757-8. PMID: 16258483.
      View in: PubMed
    124. Sawyers C. Calculated resistance in cancer. Nat Med. 2005 Aug; 11(8):824-5. PMID: 16079872.
      View in: PubMed
    125. Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, Milanov ZV, Atteridge CE, Biggs WH, Edeen PT, Floyd M, Ford JM, Grotzfeld RM, Herrgard S, Insko DE, Mehta SA, Patel HK, Pao W, Sawyers C, Varmus H, Zarrinkar PP, Lockhart DJ. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A. 2005 Aug 02; 102(31):11011-6. PMID: 16046538; PMCID: PMC1180625.
    126. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers C, Nowak MA. Dynamics of chronic myeloid leukaemia. Nature. 2005 Jun 30; 435(7046):1267-70. PMID: 15988530.
      View in: PubMed
    127. Kim JH, Kim B, Cai L, Choi HJ, Ohgi KA, Tran C, Chen C, Chung CH, Huber O, Rose DW, Sawyers C, Rosenfeld MG, Baek SH. Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes. Nature. 2005 Apr 14; 434(7035):921-6. PMID: 15829968.
      View in: PubMed
    128. Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers C. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci U S A. 2005 Mar 01; 102(9):3395-400. PMID: 15705718; PMCID: PMC552942.
    129. Graeber TG, Sawyers C. Cross-species comparisons of cancer signaling. Nat Genet. 2005 Jan; 37(1):7-8. PMID: 15624012.
      View in: PubMed
    130. Waldherr C, Mellinghoff IK, Tran C, Halpern BS, Rozengurt N, Safaei A, Weber WA, Stout D, Satyamurthy N, Barrio J, Phelps ME, Silverman DH, Sawyers C, Czernin J. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET. J Nucl Med. 2005 Jan; 46(1):114-20. PMID: 15632041.
      View in: PubMed
    131. Thomas GV, Horvath S, Smith BL, Crosby K, Lebel LA, Schrage M, Said J, De Kernion J, Reiter RE, Sawyers C. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clin Cancer Res. 2004 Dec 15; 10(24):8351-6. PMID: 15623612.
      View in: PubMed
    132. Sawyers C. Targeted cancer therapy. Nature. 2004 Nov 18; 432(7015):294-7. PMID: 15549090.
      View in: PubMed
    133. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers C. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell. 2004 Nov; 6(5):517-27. PMID: 15542435.
      View in: PubMed
    134. Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers C, Bhatia R. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood. 2005 Mar 01; 105(5):2093-8. PMID: 15345592.
      View in: PubMed
    135. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A, Sawyers C, Weissman IL. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004 Aug 12; 351(7):657-67. PMID: 15306667.
      View in: PubMed
    136. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers C. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004 Jul 16; 305(5682):399-401. PMID: 15256671.
      View in: PubMed
    137. Mellinghoff IK, Sawyers C. TORward AKTually useful mouse models. Nat Med. 2004 Jun; 10(6):579-80. PMID: 15170198.
      View in: PubMed
    138. Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, Sawyers C, Rosamilia M, Ford J, Lloyd P, Capdeville R. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 2004 Mar 01; 22(5):935-42. PMID: 14990650.
      View in: PubMed
    139. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers C. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004 Jan; 10(1):33-9. PMID: 14702632.
      View in: PubMed
    140. Sawyers C. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev. 2003 Dec 15; 17(24):2998-3010. PMID: 14701871.
      View in: PubMed
    141. Sawyers C. Will mTOR inhibitors make it as cancer drugs? Cancer Cell. 2003 Nov; 4(5):343-8. PMID: 14667501.
      View in: PubMed
    142. Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, Sawyers C, Lichtenstein AK. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem. 2004 Jan 23; 279(4):2737-46. PMID: 14576155.
      View in: PubMed
    143. Shah NP, Sawyers C. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene. 2003 Oct 20; 22(47):7389-95. PMID: 14576846.
      View in: PubMed
    144. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV, Sawyers C. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell. 2003 Sep; 4(3):223-38. PMID: 14522256.
      View in: PubMed
    145. Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers C, Mischel PS. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 2003 Jun 01; 63(11):2742-6. PMID: 12782577.
      View in: PubMed
    146. Yang H, Berger F, Tran C, Gambhir SS, Sawyers C. MicroPET imaging of prostate cancer in LNCAP-SR39TK-GFP mouse xenografts. Prostate. 2003 Apr 01; 55(1):39-47. PMID: 12640659.
      View in: PubMed
    147. Huron DR, Gorre ME, Kraker AJ, Sawyers C, Rosen N, Moasser MM. A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin Cancer Res. 2003 Apr; 9(4):1267-73. PMID: 12684394.
      View in: PubMed
    148. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers C, Arber DA, Slovak ML, Forman SJ. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. 2003 Jun 15; 101(12):4701-7. PMID: 12576334.
      View in: PubMed
    149. Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers C. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood. 2002 Oct 15; 100(8):3041-4. PMID: 12351420.
      View in: PubMed
    150. Mellinghoff IK, Tran C, Sawyers C. Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res. 2002 Sep 15; 62(18):5254-9. PMID: 12234993.
      View in: PubMed
    151. Ottmann OG, Druker BJ, Sawyers C, Goldman JM, Reiffers J, Silver RT, Tura S, Fischer T, Deininger MW, Schiffer CA, Baccarani M, Gratwohl A, Hochhaus A, Hoelzer D, Fernandes-Reese S, Gathmann I, Capdeville R, O'Brien SG. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002 Sep 15; 100(6):1965-71. PMID: 12200353.
      View in: PubMed
    152. Mellinghoff IK, Sawyers C. The emergence of resistance to targeted cancer therapeutics. Pharmacogenomics. 2002 Sep; 3(5):603-23. PMID: 12223047.
      View in: PubMed
    153. Berger F, Lee YP, Loening AM, Chatziioannou A, Freedland SJ, Leahy R, Lieberman JR, Belldegrun AS, Sawyers C, Gambhir SS. Whole-body skeletal imaging in mice utilizing microPET: optimization of reproducibility and applications in animal models of bone disease. Eur J Nucl Med Mol Imaging. 2002 Sep; 29(9):1225-36. PMID: 12418463.
      View in: PubMed
    154. Laitinen S, Karhu R, Sawyers C, Vessella RL, Visakorpi T. Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization. Genes Chromosomes Cancer. 2002 Sep; 35(1):66-73. PMID: 12203791.
      View in: PubMed
    155. Sawyers C. Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor. J Clin Oncol. 2002 Sep 01; 20(17):3568-9. PMID: 12202652.
      View in: PubMed
    156. Hess P, Pihan G, Sawyers C, Flavell RA, Davis RJ. Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts. Nat Genet. 2002 Sep; 32(1):201-5. PMID: 12161751.
      View in: PubMed
    157. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers C. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002 Aug; 2(2):117-25. PMID: 12204532.
      View in: PubMed
    158. Thomas M, Laura R, Hepner K, Guccione E, Sawyers C, Lasky L, Banks L. Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation. Oncogene. 2002 Aug 01; 21(33):5088-96. PMID: 12140759.
      View in: PubMed
    159. Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers C, Van Etten RA. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci U S A. 2002 Aug 06; 99(16):10700-5. PMID: 12149456; PMCID: PMC125018.
    160. Gery S, Sawyers C, Agus DB, Said JW, Koeffler HP. TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene. 2002 Jul 18; 21(31):4739-46. PMID: 12101412.
      View in: PubMed
    161. Braziel RM, Launder TM, Druker BJ, Olson SB, Magenis RE, Mauro MJ, Sawyers C, Paquette RL, O'Dwyer ME. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Blood. 2002 Jul 15; 100(2):435-41. PMID: 12091333.
      View in: PubMed
    162. Vivanco I, Sawyers C. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002 Jul; 2(7):489-501. PMID: 12094235.
      View in: PubMed
    163. Gorre ME, Sawyers C. Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol. 2002 Jul; 9(4):303-7. PMID: 12042704.
      View in: PubMed
    164. Sawyers C. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell. 2002 Jun; 1(5):413-5. PMID: 12124170.
      View in: PubMed
    165. Sawyers C, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O'Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002 May 15; 99(10):3530-9. PMID: 11986204.
      View in: PubMed
    166. Holtz MS, Slovak ML, Zhang F, Sawyers C, Forman SJ, Bhatia R. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood. 2002 May 15; 99(10):3792-800. PMID: 11986238.
      View in: PubMed
    167. Chen CD, Sawyers C. NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol. 2002 Apr; 22(8):2862-70. PMID: 11909978; PMCID: PMC133743.
    168. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers C. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002 Mar 15; 99(6):1928-37. PMID: 11877262.
      View in: PubMed
    169. Sawyers C, Sausville EA. Overview: the art of cancer drug screening: molecular target versus milieu-based screens. Curr Opin Investig Drugs. 2002 Mar; 3(3):478-81. PMID: 12054100.
      View in: PubMed
    170. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002 Feb 28; 346(9):645-52. PMID: 11870241.
      View in: PubMed
    171. Sawyers C. Rational therapeutic intervention in cancer: kinases as drug targets. Curr Opin Genet Dev. 2002 Feb; 12(1):111-5. PMID: 11790564.
      View in: PubMed
    172. Sawyers C. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Cancer Cell. 2002 Feb; 1(1):13-5. PMID: 12086882.
      View in: PubMed
    173. Sawyers C. Cancer treatment in the STI571 era: what will change? J Clin Oncol. 2001 Sep 15; 19(18 Suppl):13S-16S. PMID: 11560965.
      View in: PubMed